Evidence map›Paper›PMID 30015793›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2018

Pediatric Neurodevelopmental Functioning After In Utero Exposure to Triple-NRTI vs. Dual-NRTI + PI ART in a Randomized Trial, Botswana.

Deborah Kacanek, Paige L Williams, Gloria Mayondi, Penny Holding, Jean Leidner, Kebaiphe Moabi, Vicki Tepper, Sharon Nichols, Joseph Makhema, Haruna Jibril and 4 more

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Deborah KacanekDepartment of Biostatistics, Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA.
Paige L WilliamsDepartment of Biostatistics, Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA.
Gloria MayondiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Penny HoldingIdentitea Consulting, Nairobi, Kenya.
Jean LeidnerGoodtables Consulting, Norman, OK.
Kebaiphe MoabiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Vicki TepperDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, MD.
Sharon NicholsDepartment of Neurosciences, University of California San Diego, San Diego, CA.
Joseph MakhemaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Haruna JibrilBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Tebogo MadidimaloBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Roger ShapiroBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Betsy KammererDepartment of Psychiatry, Boston Children's Hospital, Boston, MA.
Botswana Harvard AIDS Institute Partnership · BWCancer Research And Biostatistics · USMinistry of Health · BWBeth Israel Deaconess Medical Center · USBoston Children's Hospital · USHarvard University · USUniversity of California, San Diego · USUniversity of Maryland, Baltimore · US

Funding

HAART to Prevent HIV Transmission to Infants In BotswanaU01AI066454 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SHAPIRO, ROGER L · 2005 to 2010
$5.3M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Effects of HIV and ARV Exposure on Child Health and Neurodevelopment in Botswana.R01MH087344 · NIMH · HARVARD SCHOOL OF PUBLIC HEALTH · PI KAMMERER, BETSY, LOCKMAN, SHAHIN · 2009 to 2013
$2.9M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
FIC NIH HHS D43 TW009610NIAID NIH HHS K24 AI131928NIAID NIH HHS U01 AI066454NIMH NIH HHS R01 MH087344
6 · The paper itself

Abstract

backgroundIn utero exposure to nucleoside reverse transcriptase inhibitor (NRTI)-containing antiretroviral treatment (ART) regimens may be associated with poor neurodevelopmental functioning in children of HIV-infected mothers. We investigated neurodevelopmental outcomes of HIV-exposed uninfected (HEU) children of HIV-infected women enrolled in a randomized trial of abacavir/zidovudine/lamivudine (triple-NRTI regimen) vs. lopinavir/ritonavir/zidovudine/lamivudine [dual-NRTI + protease inhibitor (PI) regimen].

settingThe Mma Bana randomized trial was conducted in urban and rural sites in Botswana.

methodsThe Mma Bana study randomized HIV-infected pregnant women with CD4 ≥200 cells per mm to a triple-NRTI vs. dual-NRTI + PI regimen from 26- to 34-week gestation through planned weaning at 6-month postpartum. Partway through the study, neurodevelopmental assessments were added at 24 months of age, including the Developmental Milestones Checklist, the Bayley Scales of Infant and Toddler Development third edition, Ten Questions Questionnaire, and Profile of Social Emotional Development. We evaluated differences in mean scores between the 2 arms using unadjusted and adjusted linear regression.

resultsA total of 197 HEU infants (48% male) completed a neurodevelopmental assessment (101 in triple-NRTI arm and 96 in dual-NRTI + PI-exposed arm). Mean values for all neurodevelopmental outcomes were similar for children of mothers randomized to either ART regimen, with no significant differences in either unadjusted or adjusted models (estimated effect sizes ranging from -0.12 to 0.14).

conclusionsNeurodevelopmental outcomes in 24-month-old HEU children of HIV-infected mothers with baseline CD4 ≥200 were similar in those randomized to a dual-NRTI + PI-based vs. a triple-NRTI-based ART regimen, suggestive of lack of short-term toxicity. Monitoring of long-term toxicity and newer regimens is warranted.

Indexed as

Child DevelopmentMaternal-Fetal ExchangeAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBotswanaFemaleHIV InfectionsHIV Protease InhibitorsHumansInfantInfant, NewbornNeurodevelopmental DisordersPregnancyPregnancy Complications, InfectiousReverse Transcriptase InhibitorsAnti-HIV AgentsHIV Protease InhibitorsReverse Transcriptase Inhibitors

Identifiers

PMID30015793
PMCPMC6354587
OpenAlexW2884965680

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.